OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026)
OmniAb (OABI) reported Total Non-Current Liabilities of $30.9 million for Q1 2026, down 5.06% year-over-year from $32.6 million in Q1 2025, and down 8.52% quarter-over-quarter from $33.8 million in Q4 2025.
OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Total Non-Current Liabilities data on file, last reported at $30.9 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $30.9 million, down 5.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.9 million (down 5.06% YoY), and the FY2025 annual result was $33.8 million, down 10.69% from the prior year.
- Total Non-Current Liabilities fell to $30.9 million in Q1 2026 per OABI's latest filing, from $33.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $79.8 million in Q4 2022 and troughed at $30.9 million in Q1 2026.
- A 5-year average of $48.2 million and a median of $40.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities climbed 22.13% in 2022, then plunged 38.44% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $79.8 million in 2022, then declined by 28.02% to $57.4 million in 2023, then sank by 34.09% to $37.9 million in 2024, then dropped by 10.69% to $33.8 million in 2025, then retreated by 8.52% to $30.9 million in 2026.
- Business Quant data shows OABI's Total Non-Current Liabilities at $30.9 million in Q1 2026, $33.8 million in Q4 2025, and $31.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 30.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.93 Mn |
| Dec 31, 2025 | 33.81 Mn |
| Sep 30, 2025 | 31.73 Mn |
| Jun 30, 2025 | 33.53 Mn |
| Mar 31, 2025 | 32.58 Mn |
| Dec 31, 2024 | 37.85 Mn |
| Sep 30, 2024 | 39.77 Mn |
| Jun 30, 2024 | 41.89 Mn |
| Mar 31, 2024 | 51.13 Mn |
| Dec 31, 2023 | 57.44 Mn |
| Sep 30, 2023 | 63.64 Mn |
| Jun 30, 2023 | 68.05 Mn |
| Mar 31, 2023 | 72.20 Mn |
| Dec 31, 2022 | 79.79 Mn |
| Dec 31, 2021 | 65.33 Mn |